Health Trials

T-ALL/Lymphoma

2

Review clinical trials related to T-ALL/Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.

Participants needed: 90
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Tianjin Medical University General HospitalUpdated: Apr 4, 2025Locations: 1
Eligibility criteria

Not listed

Read more
Status: Recruiting

Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.

Participants needed: 15
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Chongqing Precision Biotech Co., LtdUpdated: Apr 3, 2025Locations: 1
Eligibility criteria

Refractory to ≥2 cycles of standard induction chemotherapy (failure to achieve C... [+9]

Prior CAR-NK therapy or genetically modified cell therapy. [+17]

Read more